DMAC

DIAMEDICA THERAPEUTICS INC

DMAC·25253X207·US·Common Stock·Healthcare - Biotechnology-13D/G

DMAC (DIAMEDICA THERAPEUTICS INC) is held by 59 institutional investors as of Q2 2026. Largest holders: COOPERMAN LEON G ($24.3M), BlackRock, Inc. ($15.9M), GEODE CAPITAL MANAGEMENT, LLC ($6.3M). Net institutional sentiment: Mixed.

59
Holders
(7 Elite)
$79.1M
Total Value
63% (59)
Consensus
37 buying - 22 selling
13F: Insider & Congress: Updated regularly
DMAC

Smart Money Verdict

View all
Loading verdict
Held by 59 funds
7 elite

Who's Trading

Source dates: Price Aug 28, 2026 · Insiders Dec 8, 2025 · Activists Feb 17, 2026 · Congress none

ActivistCLCooperman Leon G.6.6%Feb 17, 2026
ActivistDLDialectic Life Sciences SPV LLC0.0%Feb 17, 2026
ActivistTATRILL AB16.9%Feb 6, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
3.5M(+70.8%)$24.3M0.7%+13.13%
61
Increased
2.3M(+21.3%)$15.9M0.0%+21.25%
34
Increased
894,115(+14.6%)$6.3M0.0%+30.04%
31
Decreased
845,309(-9.7%)$6M0.0%-5.00%
0
Increased
646,743(+0.4%)$4.6M0.0%+12.92%
27
Increased
355,523(+6.6%)$2.5M0.0%-12.63%
28
Increased
338,107(+5.8%)$2.4M0.0%+11.82%
28
Decreased
327,518(-3.3%)$2.3M0.0%+46.95%
0
Increased
251,671(+23.7%)$1.8M0.0%-11.63%
31
Increased
233,500(+3.3%)$1.6M0.0%+43.36%
27
Increased
207,438(+10.5%)$1.5M0.0%-12.38%
28
Increased
168,066(+183.5%)$1.2M0.0%-4.93%
41
Increased
145,870(+0.1%)$1M0.0%-9.77%
25
New
145,247$1M0.0%-4.83%
35
Increased
117,820(+6.1%)$829,4490.0%+12.74%
26
Increased
96,691(+9.3%)$680,7050.0%+42.14%
27
Increased
84,648(+280.3%)$595,9220.0%-8.29%
39
Increased
57,712(+34.9%)$406,2920.0%-4.33%
21
Increased
54,944(+194.8%)$386,8060.0%+1.58%
38
Decreased
48,349(-38.9%)$340,3770.0%+5.79%
0

Showing 1-20 of 69

1 / 4
DMACDMACDIAMEDICA THERAPEUTICS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used